Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0KUBYR
ADC Name	Ab3-mcMMAF
Synonyms	Ab3-mc-MMAF Click to Show/Hide
Organization	Abbvie Inc
Drug Status	Investigative
Indication	In total 1 Indication(s) Lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	3.1
	3D MOL	2D MOL
Antibody Name	Anti-EGFR Ab3		Antibody Info
Antigen Name	Epidermal growth factor receptor (EGFR)		Antigen Info
Payload Name	Monomethyl auristatin F		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Maleimido-caproyl		Linker Info

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 30.23	%	CVCL_2891	Lung squamous cell carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 30.23% (Day 33)	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg to thetail of each mouse.
In Vivo Model	EBC-1 CDX model
In Vitro Model	Lung squamous cell carcinoma	EBC-1 cells		CVCL_2891

References

Ref 1	Anti-egfr antibodies and antibody drug conjugates.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.